hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06293807, orgStudyIdInfo id: 20220162HU, briefTitle: Immediate Post-Operative Anesthesia With Either Lidocaine or Bupivacaine, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-06-06, primaryCompletionDateStruct date: 2023-04-16, completionDateStruct date: 2023-04-16, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: The University of Texas Health Science Center at San Antonio, class: OTHER, descriptionModule briefSummary: Immediate post-suturing administration of either one of two dental anesthetic solutions or a placebo prior to dismissal., conditionsModule conditions: Periodontal Diseases, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: A randomized, placebo-controlled, parallel design study., primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Both the surgeon and patient will be blinded as to the intervention provided by covering identifying marks of the anesthetic carpules to be administered. Randomization will be assured by random selection of a slip of paper drawn from a sealed envelope assigning the patient to one of three groups., whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 72, type: ACTUAL, armsInterventionsModule interventions name: Xylocaine 2 % with 1:100,000 epinephrine, interventions name: Bupivicaine 0.5% with 1:200,000 epinephrine, interventions name: Placebo, outcomesModule primaryOutcomes measure: Change in pain using Visual Analog Scale (VAS), primaryOutcomes measure: Number of Ibuprofen administered, primaryOutcomes measure: Number of Tylenol administered, secondaryOutcomes measure: Arch Response, secondaryOutcomes measure: Number of teeth, secondaryOutcomes measure: Type of procedure, secondaryOutcomes measure: Gender of patient, secondaryOutcomes measure: Age of patient, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The University of Texas Health Science Center at San Antonio, city: San Antonio, state: Texas, zip: 78229, country: United States, geoPoint lat: 29.42412, lon: -98.49363, hasResults: False
protocolSection identificationModule nctId: NCT06293794, orgStudyIdInfo id: 22-0991, briefTitle: Decision Support for Heart Failure Prescribing, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2025-09, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: University of Colorado, Denver, class: OTHER, descriptionModule briefSummary: Clinical decision support (CDS) tools can 'nudge' clinicians to make the best decisions easy. Although required by "meaningful use" regulations, more than 40% of CDS lead to no change and the remaining lead to improvements that are modest at best. This is because CDS tools often ignore contextual factors and present irrelevant information. Although many tools have undergone patient-specific optimization, 'traditional CDS' are rarely clinician-specific. For example, a traditional CDS tool for beta blockers and heart failure with reduced ejection fraction (HFrEF) addresses common prescribing misconceptions by stating asthma is not a contraindication and providing a safe threshold for blood pressure. For clinicians without these misconceptions, these statements are irrelevant and distract from key information. A 'personalized CDS' would evaluate clinician past prescribing patterns to determine whether prescribing misconceptions might exist and then conditionally present information to address those misconceptions. The objective of this research is to create personalized clinician-specific CDS that overcome shortcomings of traditional CDS. The central hypothesis is a personalized CDS that minimizes irrelevant information will lead to a higher rate of prescribing guideline-directed management and therapy (GDMT) for HFrEF compared to a traditional CDS., conditionsModule conditions: Decision Support Systems, Clinical, conditions: Heart Failure, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Compare traditional and personalized CDS in a pragmatic randomized controlled trial at one health system., primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 1075, type: ESTIMATED, armsInterventionsModule interventions name: Personalized Clinical Decision Support (CDS), interventions name: Traditional Clinical Decision Support (CDS), outcomesModule primaryOutcomes measure: Number of CDS alerts resulting in the prescription of a recommended medication, secondaryOutcomes measure: Number of patients the CDS alerted for, secondaryOutcomes measure: Number of alerts that were not outright dismissed, secondaryOutcomes measure: Number of prescription orders for guideline directed management and therapies (GDMT) for heart failure, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 89 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06293781, orgStudyIdInfo id: GachonU, briefTitle: Application of the Web-based Acceptance and Commitment Therapy for Depression, acronym: ACTION, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-12-19, primaryCompletionDateStruct date: 2025-02-28, completionDateStruct date: 2025-02-28, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Gachon University, class: OTHER, descriptionModule briefSummary: PROSPECTIVE INTERVENTION STUDY; EFFICACY OF WEB-BASED ACCEPTANCE AND COMMITMENT THERAPY, conditionsModule conditions: Major Depressive Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Web-based ACT, interventions name: Treatment as usual, outcomesModule primaryOutcomes measure: Acceptance and Action Questionnaire-II, secondaryOutcomes measure: Cognitive Fusion Questionnaire, eligibilityModule sex: ALL, minimumAge: 19 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Kyoung-Sae Na, status: RECRUITING, city: Incheon, state: Please Incheon, zip: 21565, country: Korea, Republic of, contacts name: Kyoung-Sae Na, MD, PhD, role: CONTACT, phone: 82324689932, email: ksna13@gmail.com, geoPoint lat: 37.45646, lon: 126.70515, hasResults: False
protocolSection identificationModule nctId: NCT06293768, orgStudyIdInfo id: FADOI.05.2018, briefTitle: Continuous Wireless Monitoring for Patients in the Internal Medicine UOC. Randomized Controlled Trial (GreenLineH-T), acronym: GreenLineH-T, statusModule overallStatus: COMPLETED, startDateStruct date: 2019-09-23, primaryCompletionDateStruct date: 2023-12-31, completionDateStruct date: 2024-02-20, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Fadoi Foundation, Italy, class: OTHER, descriptionModule briefSummary: Monocentric prospective controlled randomized in open-label study. The study involves the enrollment of 300 patients (150 patients undergoing continuous monitoring and 150 as a control), aim of the study is to evaluate in these patients the efficacy of a continuous telemonitoring of the patient's clinical condition for 5 days compared to a traditional clinical monitoring., conditionsModule conditions: Hospitalization, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, interventionModelDescription: The study involves the enrollment of 300 patients (150 patients undergoing continuous monitoring and 150 as a control). 50 of the patients undergoing continuous monitoring come from the group A and 100 from group B, same ratio in the control group.Group A includes patients admitted to the acute ward who are considered transferable to the ward for subacute by the seventh day of hospitalization. Group B includes patients admitted to the acute ward who are considered dismissible by the seventh day of hospitalization, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 208, type: ACTUAL, armsInterventionsModule interventions name: continuous wireless monitoring system of Vital Signs (Win@Hospital) + continuous system for continuous monitoring of blood sugar (Dexcom G6)(only for diabetic patients), outcomesModule primaryOutcomes measure: difference in the incidence of major complications at 30 days, secondaryOutcomes measure: number of acute patients who in seven days reach the criteria to be discharged or ransferred to the subacute ward, secondaryOutcomes measure: Difference in the incidence of major complications at the end of the telemonitoring phase, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ospedale di Albano - Polo H2, city: Roma, country: Italy, geoPoint lat: 41.89193, lon: 12.51133, hasResults: False
protocolSection identificationModule nctId: NCT06293755, orgStudyIdInfo id: COA022/66, briefTitle: Microneedle Patch With Botulinum Toxin in Management of Enlarged Facial Pores, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-02-28, primaryCompletionDateStruct date: 2024-03-05, completionDateStruct date: 2024-06-25, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Dhurakij Pundit University, class: OTHER, descriptionModule briefSummary: The purpose of this study is to assess the efficacy and safety of microneedle patch with botulinum toxin for improving enlarged pores., conditionsModule conditions: Enlarged Pores, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 16, type: ESTIMATED, armsInterventionsModule interventions name: Microneedle patch, interventions name: Intradermal injection, outcomesModule primaryOutcomes measure: Change from baseline of enlarged pores as measured by VISIA (pores parameter) and using pore score, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Dhurakij Pundit University, city: Lak Si, state: Bangkok, country: Thailand, geoPoint lat: 13.88724, lon: 100.5792, hasResults: False
protocolSection identificationModule nctId: NCT06293729, orgStudyIdInfo id: NGGT006-P-2302, briefTitle: Safety and Efficacy Study of NGGT006 in Refractory Hypercholesterolemia Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-03-31, completionDateStruct date: 2029-03-01, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Suzhou Municipal Hospital, class: OTHER, descriptionModule briefSummary: This is an early phase 1, open-label, single-center, dose-escalation pilot trial to evaluate the safety and efficacy of an intravenous infusion of NGGT006 in patients with refractory Hypercholesterolemia diagnosed by gene testing for familial hypercholesterolemia. NGGT006 uses adeno-associated virus (AAV) as a vector, carrying a liver specific promoter and codon optimized human LDLR gene, driving the expression of LDLR protein with normal function and promoting the clearance of low-density lipoprotein cholesterol (LDL-C)., conditionsModule conditions: Refractory Hypercholesterolemia, conditions: Familial Hypercholesterolemia, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 9, type: ESTIMATED, armsInterventionsModule interventions name: NGGT006, outcomesModule primaryOutcomes measure: Incidence of treatment-related adverse events (AE) and serious adverse events (SAE), primaryOutcomes measure: Absolute change and percent change in LDL-C, secondaryOutcomes measure: Absolute change and percent change in non-high density lipoprotein cholesterol, secondaryOutcomes measure: Absolute change and percent change in apolipoprotein B, secondaryOutcomes measure: Absolute change and percent change in total cholesterol, secondaryOutcomes measure: Absolute change and percent change in HDL-C, secondaryOutcomes measure: Absolute change and percent change in triglycerides, secondaryOutcomes measure: Absolute change and percent change in very low-density lipoprotein cholesterol, secondaryOutcomes measure: Absolute change and percent change in lipoprotein(a), secondaryOutcomes measure: Absolute change and percent change in apolipoprotein A-I, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06293716, orgStudyIdInfo id: CVL237-A2001, briefTitle: CVL237 Tablets for APDS/PASLI, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-30, primaryCompletionDateStruct date: 2025-12-29, completionDateStruct date: 2026-03-30, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Convalife (Shanghai) Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: This study was designed to evaluate the efficacy and safety of CVL237 tablets in patients with APDS/PASLI (activated phosphoinositol 3-kinase δ syndrome /p110 delta-activated mutation leading to senescent T cells, lymphadenopathy, and immune deficiency)., conditionsModule conditions: PI3K and P110delta Hyperactivation Syndrome, designModule studyType: INTERVENTIONAL, phases: PHASE2, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: CVL237 tablets for APDS/PASLI (Activated phosphoinositol 3-kinase delta syndrome /p110 delta-activated Mutation leading to senescent T cells, lymphadenopathy, and immune deficiency), primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Part II is a randomized, double-blind, placebo-controlled study of approximately 30 patients with APDS/PASLI. On day 1, patients were randomly assigned to the trial and placebo groups in a 2:1 ratio to take an oral CVL237 tablet or a placebo CVL237 simulant once daily. Efficacy and safety were evaluated on days 29, 57, and 85. The efficacy of CVL237 tablets in reducing lymphadyopathy will be investigated as measured by changes in the sum of diameter products (SPD) of target lesions selected from MRI or CT imaging according to the Lugano 2014 method, as well as changes in the percentage of naive B cells to total B cells, relative to baseline. The CVL237 tablets will also be evaluated for safety, PK, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 35, type: ESTIMATED, armsInterventionsModule interventions name: CVL237 tablets, interventions name: CVL237 placebo tablets, outcomesModule primaryOutcomes measure: part 1 : Incidence of Treatment-Emergent Adverse Events, primaryOutcomes measure: part 2:After 84 days of treatment, changes in the sum of diameter product (SPD) of log10 conversion in target lesions and changes in the percentage of naive B cells to total B cells from baseline were observed, secondaryOutcomes measure: Cmax, secondaryOutcomes measure: t1/2, secondaryOutcomes measure: AUC, secondaryOutcomes measure: Tmax, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shanghai Public Health Clinical Center, city: Shanghai, state: Shanghai, zip: 201508, country: China, contacts name: Yun Ling, ph.D, role: CONTACT, phone: 18121157875, email: yun.ling@vip.126.com, contacts name: Ying Lv, role: CONTACT, phone: 18916099680, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06293703, orgStudyIdInfo id: 23-1228, briefTitle: Effect of Limb Length Ratio on Roux-en-Y Gastric Bypass Outcomes (CLIMB II Study), acronym: CLIMB II, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-12, primaryCompletionDateStruct date: 2025-12-11, completionDateStruct date: 2030-12-11, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Salvador Navarrete, class: OTHER, descriptionModule briefSummary: The investigators propose a randomized controlled trial comparing BP and roux limb lengths measuring 30 and 15% respectively of patient's total small bowel length versus current standard practice using fixed lengths. The findings would provide further insight into feasibility of standardizing RYGB limb lengths and optimizing resultant weight loss and metabolic effects. The investigators hypothesize RYGB with ratio-adjusted limb lengths (aRYGB) will result in higher total weight loss and resolution of metabolic syndrome comorbidities, including diabetes, hyperlipidemia, and hypertension compared to standard fixed-length RYGB (sRYGB). The study will also utilize the Short Form Rand 36-Item Health Survey (SF36) to determine differences in postoperative quality of life metrics., conditionsModule conditions: Morbid Obesity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This study will be a prospective, randomized controlled trial with a 1:1 recruitment allocation ratio coordinated at the Cleveland Clinic Foundation (CCF), primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 262, type: ESTIMATED, armsInterventionsModule interventions name: Surgery, outcomesModule primaryOutcomes measure: To determine change in TWL after aRYGB compared to sRYGB in morbidly obese patients, secondaryOutcomes measure: To compare rates of DM resolution between aRYGB Vs sRYGB by DM subgroup analysis, secondaryOutcomes measure: To investigate postoperative efficacy rates of aRYGB compared to sRYGB on alleviating metabolic syndrome in morbid obesity, secondaryOutcomes measure: To investigate the presence of postoperative vitamin and nutritional deficiencies between the groups., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Cleveland clinic, status: RECRUITING, city: Cleveland, state: Ohio, zip: 44195, country: United States, contacts name: Salvador Navarrete, MD, role: CONTACT, phone: 216-219-9211, email: navarrs@ccf.org, geoPoint lat: 41.4995, lon: -81.69541, hasResults: False
protocolSection identificationModule nctId: NCT06293690, orgStudyIdInfo id: L23-407, briefTitle: Toripalimab Combined With SBRT for NSCLC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2025-06-30, completionDateStruct date: 2026-06-30, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Shanghai Pulmonary Hospital, Shanghai, China, class: OTHER, descriptionModule briefSummary: This study aimed to evaluate the efficacy and safety of Toripalimab injection (js001) combined with SBRT radiotherapy and neoadjuvant therapy with or without chemotherapy for operable or potentially operable stage IIa to IIIb NSCLC, conditionsModule conditions: Non-small Lung Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Toripalimab, interventions name: Toripalimab, outcomesModule primaryOutcomes measure: Major pathological remission rate, secondaryOutcomes measure: Complete pathological remission rate, secondaryOutcomes measure: disease-free survival（DFS）, secondaryOutcomes measure: overall survival, otherOutcomes measure: Adverse events, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shanghai Pulmonary Hospital, city: Shanghai, state: Shanghai, zip: 200000, country: China, contacts name: Deping Zhao, role: CONTACT, phone: 0086-20-65115006, email: zdp1992@163.com, contacts name: Deping Zhao, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06293664, orgStudyIdInfo id: RAHM-2023-006, briefTitle: Protocol for Alpha MSH Infusion Study in Patients With Type 2 Diabetes, acronym: α-MSH & T2DM, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-04, primaryCompletionDateStruct date: 2024-04-04, completionDateStruct date: 2024-04-04, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Dasman Diabetes Institute, class: OTHER, descriptionModule briefSummary: Alpha-melanocyte stimulatory hormone (α-MSH) is a melanocyte-stimulating hormone produced by the hypothalamus and released from the pituitary gland. It acts as an agonist to the melanocortin 5 receptor (MC5R) in human skeletal muscle, playing a role in glucose uptake and disposal. This study aims to investigate whether α-MSH can enhance glucose tolerance in patients with Type 2 Diabetes Mellitus (T2DM)., conditionsModule conditions: Type 2 Diabetes Mellitus, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: The research involves a double-blinded, randomized, placebo-controlled crossover study to assess the therapeutic potential of α-MSH infusion in T2DM patients., primaryPurpose: SCREENING, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 13, type: ESTIMATED, armsInterventionsModule interventions name: α-MSH infusion, interventions name: Placebo solutions, outcomesModule primaryOutcomes measure: Difference in the total or incremental area under the curve of glucose and insulin concentration at an OGTT during saline vs. α-MSH infusion, secondaryOutcomes measure: Difference in the total or incremental area under the curve of the concentration of metabolites (C-peptide, Glucagon, Gut hormones, α-MSH) during OGTT with saline or α-MSH infusion., otherOutcomes measure: Difference in energy intake measured by an ad libitum meal test at the saline vs. α-MSH infusion, otherOutcomes measure: Adverse events (including flushing), eligibilityModule sex: ALL, minimumAge: 21 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Dasman Diabetes Institute, status: RECRUITING, city: Kuwait City, country: Kuwait, contacts name: Ebaa Al Ozairi, MD, role: CONTACT, contacts name: Dalal Alsaeed, PhD, role: CONTACT, contacts name: Carel Roux, MD, role: SUB_INVESTIGATOR, geoPoint lat: 29.36972, lon: 47.97833, hasResults: False